SynthesisFrontiers in immunology2025

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis.

Huimin Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.